Antifungal Treatments in Adult Haematology Patients - Guidelines for the use of
|Publication: 01/03/2009 --|
|Last review: 27/12/2017|
|Next review: 27/12/2020|
|Approved By: Improving Antimicrobial Prescribing Group|
|Copyright© Leeds Teaching Hospitals NHS Trust 2017|
This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated.
Guidelines for the use of Antifungal Treatments in Adult Haematology Patients
Invasive fungal disease (IFD)
|Empirical Antimicrobial Treatment|
There are at least two published comparisons of different doses of Ambisome in treating IFD. One of these demonstrates similar efficacy for Ambisome at 1 mg/kg/day vs. 4 mg/kg/day (Ellis et al. 1998) and the other shows no difference in outcome between Ambisome at 3 and 10 mg/kg/day (Cornely et al. 2007). Although the licensed dose for Ambisome in proven/probable fungal infection is 1-3 mg/kg/day, the licensed dose in febrile neutropenia, in which most patients do not have a fungal infection, is 3 mg/kg/day (presumably based on Prentice et al., 1997). Given the evidence of similar efficacy between Ambisome at 1 and 4 mg/kg/day an empiric Ambisome dose of 1 mg/kg/day is recommended in this guideline, whilst awaiting further results.
|Duration of Treatment|
It is recommended that treatment of IPA be continued for at least 6–12 weeks, largely dependent on the degree and duration of immunosuppression, site of disease, and evidence
|Please contact Microbiology if the patient is not responding to the recommended antimicrobial regimens.|
|Clinical condition:||Use of antifungal agents in adult haematology patients|
|Target patient group:||Adults|
|Target professional group(s):||Secondary Care Doctors
- Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clinical Infectious Diseases, 2002;34:7-14.
- Cornely, O. A., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomised trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clinical Infectious Diseases 2007;44:1289-97.
- De Pauw et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clinical Infectious Diseases 2008;46:1813-21.
- Ellis, M., et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clinical Infectious Diseases 1998;27:1406-12.
- Prentice AG, Glasmacher A, Hobson RP, Schey S , Barnes RA, Donnelly JP, Jackson G. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. British Committee for Standards in Haematology 2008; published on line at http://www.bcshguidelines.com/pdf/IFI_therapy.pdf
- Prentice, H. G., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology1997;98;711-18.
- Walsh, T. J., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New England Journal of Medicine 1999;340: 764-71.
- Patterson, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 63(4):e1-e60.
- Maertens JA, et al. 2016 Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 387:760-9
A. Meta-analyses, randomised controlled trials/systematic reviews of RCTs
B. Robust experimental or observational studies
C. Expert consensus.
D. Leeds consensus. (where no national guidance exists or there is wide disagreement with a level C recommendation or where national guidance documents contradict each other)
Improving Antimicrobial Prescribing Group
LHP version 1.0
Equity and Diversity
The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.